LUCIUS 卢修斯 哌柏西利 Palbociclib转移性乳腺癌

哌柏西利

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Palbociclib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Compesition:
Ench capsule contains Palbeciclib ............. 100mg

LUCiUS

转移性乳腺癌

LuciPalhoisa kin
Lucir a00 1s 2 kinase inhibitor indicated for tne

PHARMACEUTICALS

ueatlient of ddunt paltents wtn normone receoto
tuman enidermal arnuih foefae

cancer in combination with
* an aromatase inhihitor as iniial endocrine-base

LuciPalbo

therapy in postmencoausal worsen or in men:or
LaciPalhe esal

beetraloo capsules are taken orally with food in

Palbociclib Capsules

ialie with an aromatese inhiitor or falvestrant.
*Recommended startino dose: 125 me once daily taken
with food for 21 davs followed br 7 davs off trestmen

100mg

FDA批准

*Dosing interruption andior dose reductions afe
oimended based on indrvidual salely and
Sterage: in a dry place and store at20C fo 25°C
Warning:

21 Capsules

cep medicine out of reash of Children, Do not
administer LaciPalho durine Preanancy and Lactatio
PLEASE SEE PACKAGE INSEK
Manufactured and Marketed by
LUCIUS

权威认证

Thongmang village, Xaythany distriet.
Vientiane Capital, Laoy
Warning: To be sold by retail on prescriotion
ed payscians only, and as directed

Rx Only

口碑质量

适应症:
适用于治疗激素受体(HR)阳性、人类表皮生长因子受体2(HER2)阴
性的晚期或转移性乳腺癌的成年患者,联合用药:
·与芳香化酶抑制剂联合使用,作为绝经后女性或男性的初始内分泌治

疗;
·与氟维司群联合使用,用于内分泌治疗后病情进展的患者。
推荐剂量:
与芳香化酶抑制剂或氟维司群一起口服:
·建议起始剂量:每日一次,每次125mg,随餐服用,连续21天,然后停
·根据个人安全性和耐受性,建议中断给药和/或减少剂量。
药7天。